ArticleEuropean journal of nuclear medicine and molecular imaging2023
Biodistribution and dosimetry for combined [
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- PSMA-targeted radioligand therapy in prostate cancer: evidence hierarchy, platform maturity of ¹⁷⁷Lu-PSMA-617, and the clinical differentiation challenge for emerging radionuclides.Annals of nuclear medicine · 2026Review
- Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [European journal of nuclear medicine and molecular imaging · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Exploring Anti-Coincidence Technique for Scattering Contamination Rejection in a Simultaneous PET/SPECT Imaging System.IEEE transactions on radiation and plasma medical sciences · 2026Article
- Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review).International journal of oncology · 2026Review
- Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [European journal of nuclear medicine and molecular imaging · 2026Article
- Performance Evaluation of Single- and Double-Layer CZT Compton Cameras forIEEE transactions on nuclear science · 2026Article
- Review
- Feasibility study ofEJNMMI physics · 2025Article
- [Options in nuclear medicine for advanced prostate cancer in practice].Radiologie (Heidelberg, Germany) · 2025Article
- Comparison of scatter and partial volume correction techniques for quantitative SPECT imaging ofEJNMMI physics · 2025Article
- [Options in nuclear medicine for advanced prostate cancer in practice].Urologie (Heidelberg, Germany) · 2025Review
- Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Biodistribution and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Gamma camera imaging characteristics ofEJNMMI physics · 2025Article
- Shorter SPECT scans using self-supervised coordinate learning to synthesize skipped projection views.EJNMMI physics · 2025Article
- Evaluating auto-contouring accuracy in reduced CT dose images for radiopharmaceutical therapies: Denoising and evaluation ofJournal of applied clinical medical physics · 2025Article
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- Optimization and application of renal depth measurement method in the cadmium-zinc-telluride‑based SPECT/CT renal dynamic imaging.EJNMMI physics · 2024Article
- Evaluation of Angiotensin-Converting Enzyme 2 ExpressionACS pharmacology & translational science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeQuantitative SPECT for patient-specific dosimetry is a valuable tool in the scope of radionuclide therapy, although its clinical application for
methodsEight prostate cancer patients (1000 MBq/8 MBq [
resultsKidney (r = 0.96, p < 0.01) and lesion (r = 0.94, p < 0.01) SUV for [
conclusionQuantitative low-count SPECT imaging of the peak at 440 keV during [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.